Back to Search
FARIDA DURRANI, MD
MD
Clinical Medical Laboratory
NPI: 1194132639Individual
Specialties, Licenses & Credentials
General Acute Care Hospital
General Acute Care Hospital
Code: 282N00000X
Clinical Medical LaboratoryPrimary
Clinical Medical Laboratory
Code: 291U00000X
Research & Publications (16)
Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.
PMID 19632930·Clin Colorectal Cancer·2009
7-preclinical
Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
PMID 18670644·Neoplasia·2008
7-preclinical
Efficacy of aniseed extract as immune stimulant and growth promoter in broiler chicks.
PMID 19093489·Pak J Biol Sci·2007
7-preclinical
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
PMID 17289892·Clin Cancer Res·2007
3-trial
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
PMID 17239826·Biochem Pharmacol·2007
7-preclinical
Effect of wild mint (Mentha longifolia) infusion on the over all performance of broiler chicks.
PMID 19070065·Pak J Biol Sci·2007
7-preclinical
Effect of different levels of feed added black seed (Nigella sativa L.) on the performance of broiler chicks.
PMID 19090301·Pak J Biol Sci·2007
7-preclinical
Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
PMID 16518418·Oncogene·2006
7-preclinical
Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
PMID 16556086·Expert Opin Pharmacother·2006
6-review
Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison.
PMID 15531731·Mol Pharmacol·2005
4-observational
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
PMID 15897249·Mol Cancer Ther·2005
7-preclinical
Synergistic antitumor activity of capecitabine in combination with irinotecan.
PMID 15663838·Clin Colorectal Cancer·2005
7-preclinical
Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
PMID 16098255·Clin Colorectal Cancer·2005
6-review
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
PMID 15585636·Clin Cancer Res·2004
7-preclinical
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
PMID 15073137·Clin Cancer Res·2004
7-preclinical
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
PMID 14871992·Clin Cancer Res·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2601 OCEAN PARKWAY
BROOKLYN, NY 11235 - Phone
- (718) 616-3000
Quick Facts
- NPI
- 1194132639
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 16
Are you this provider?
Claim Your Profile